lonafarnib has been researched along with ritonavir in 3 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (ritonavir) | Trials (ritonavir) | Recent Studies (post-2010) (ritonavir) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 5,419 | 1,291 | 2,772 |
| Protein | Taxonomy | lonafarnib (IC50) | ritonavir (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | 6.1 | |
| Bile salt export pump | Homo sapiens (human) | 2.085 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.65 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.1623 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2.3 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.458 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.067 | |
| Substance-K receptor | Homo sapiens (human) | 2.622 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 2.35 | |
| Thromboxane-A synthase | Homo sapiens (human) | 0.076 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 4.4 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.1933 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.4 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 2 | |
| Protease | Human immunodeficiency virus 1 | 4.9253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bozdayi, AM; Çalişkan, A; Glenn, JS; Heller, T; Idilman, R; Kalkan, Ç; Karakaya, F; Karatayli, E; Karatayli, S; Keskin, O; Koh, C; Yurdaydin, C | 1 |
| Apelian, D; Bozdayi, AM; Çalişkan, A; Choong, I; Glenn, JS; Heller, T; Idilman, R; Kalkan, Ç; Karakaya, F; Karatayli, E; Karatayli, S; Keskin, O; Koh, C; Önem, S; Yurdaydin, C; Yurdcu, E | 1 |
| Keskin, O; Yurdaydin, C | 1 |
2 trial(s) available for lonafarnib and ritonavir
| Article | Year |
|---|---|
Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Interferon-alpha; Male; Middle Aged; Pilot Projects; Piperidines; Pyridines; Ritonavir; RNA, Viral; Treatment Outcome; Young Adult | 2018 |
A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.
Topics: Alanine Transaminase; Drug Therapy, Combination; Hepatitis D, Chronic; HIV Infections; Humans; Interferon-alpha; Piperidines; Pyridines; Ritonavir; RNA | 2022 |
1 other study(ies) available for lonafarnib and ritonavir
| Article | Year |
|---|---|
Emerging drugs for hepatitis D.
Topics: Antiviral Agents; Hepatitis D; Hepatitis D, Chronic; Humans; Nucleic Acids; Polyethylene Glycols; Polymers; Ritonavir; Treatment Outcome | 2023 |